Search
Meet the team at Phage WA, who are working to tackle antimicrobial resistance (AMR) through phage therapy.
Our team uses AI to quickly analyse large amounts of genetic data to help discover alternate medications and improve existing treatments.
As part of our research development and planning we invite members of the community to work with us. Click here to find out how.
If you have any questions or would like more information about the Western Australian Epithelial Research Program (WAERP), please click here to access our contact details.
Ensitrelvir, a 3C-like protease inhibitor, received emergency approval in Japan in November 2022 for treating non-hospitalized patients with mild-to-moderate COVID-19. However, confirmation of its real-world clinical effectiveness is limited.